Listening is in our DNA.
Ακούω in Greek translates to Listen in English. At Akouos (ah KOO ohs), we strive to be a team that listens to one another, to healthcare providers, and to the deaf and hard of hearing (D/HH) community. Our partnerships and collaborations are focused on common goals and predicated on respect, trust, and transparency.
Common Goal Partnerships
In partnering with the D/HH community, we will use the principles outlined here as our guide.

Manny Simons, PH.Dfounder and CEO of AkouosHearing loss is one of the greatest challenges in medicine today, and with no FDA-approved pharmacologic therapies available, an area of severe unmet need.
We Are Akouos
Michael McKenna
CHIEF MEDICAL OFFICER & CO-FOUNDER
Sachiyo Minegishi
CHIEF FINANCIAL OFFICER
Stacy Price
CHIEF TECHNICAL OFFICER
Kathy Reape
CHIEF DEVELOPMENT OFFICER
Karoline Shair
CHIEF LEGAL OFFICER & CORPORATE SECRETARY
Emmanuel Simons
CEO, PRESIDENT & CO-FOUNDER
Aaron Tward
CHIEF SCIENTIFIC OFFICER
Jennifer Wellman
CHIEF OPERATING OFFICER
Our Partners

Join us in the pursuit of healthy hearing for all.
What’s at our core
We Work to Change Lives
Akouos listens: to each other, to the individuals and families we work to serve, to our collective conscience.
Akouos engages: Honestly, transparently, respectfully.
Akouos leads: Authentically, boldly, bravely, with purpose and passion.
Akouos creates: High standards, opportunities to excel, better medicines.
Akouos trusts: Ourselves, each other, our science.
Join us in the pursuit of healthy hearing for all.
Akouos is building a leading gene therapy company focused on hearing disorders. Our objectives are to restore the inner ear’s ability to produce functional proteins required for hearing, rejuvenate structures of the hearing circuit critical for high-fidelity signal transduction and inner ear homeostasis, and reinforce healthy hearing with local, enduring protein production to protect against drug-, noise-, and age- associated ototoxicity.